Article Information

Farhad Salehzadeh MD¹, Adel Ahadi MD^2*, Omid Akbari MD³

¹Professor of Pediatric Rheumatology, Pediatric Department, Ardabil University of Medical Sciences (ARUMS), Ardabil, Daneshgah st. Ardabil, Iran

²Adel Ahadi Assistant Professor of Pediatric, Pediatric Department, Bouali Children`s Hospital, Ardabil University of Medical Sciences (ARUMS), Ardabil, Iran

³Pediatric Department, Bouali Children`s Hospital, Ardabil University of Medical Sciences (ARUMS), Ardabil, Iran

^*Corresponding Author: Adel Ahadi MD, Assistant Professor of Pediatric. Pediatric Department, Bouali Children`s Hospital, Ardabil University of Medical Sciences (ARUMS), Ardabil, Iran

Received: 12 June 2023; Accepted: 20 June 2023; Published: 27 June 2023

Citation:

Farhad Salehzadeh, Adel Ahadi, Omid Akbari. Primary Central Nervous System Vasculitis in Childhood (Cpacns): A Case Series Study. Journal of Pediatrics, Perinatology and Child Health. 7 (2023): 128-133.

Abstract

Keywords

Primary CNS vasculitis; Childhood CNS vasculitis; Primary CNS angiitis

Article Details

Abbreviations:

CPACNS: Primary CNS Angiitis of Childhood; CNS: Central Nervous System; MRA: Magnetic Resonance Arteriography; MRI: Magnetic Resonance Imaging; MCA: Middle Cerebral Artery; ACA: Anterior Cerebral Artery; PCA: Posterior Cerebral Artery; HSP: Henoch-Schonlein Purpura; KD: Kawasaki Disease; VZV: Varicella Zoster Virus; ESR: Erythrocyte Sedimentation Rate; CRP: C-Reactive Protein; WBC: white Blood Cell Count; CA: CT-Angiography

1. Introduction

Vasculitis is a heterogeneous group of blood vessels disorders which characterized by inflammation, necrosis and the obstruction of the inflamed vessels [1]. Central nervous system (CNS) vasculitis of childhood is a novel recognized autoimmune brain disorder with significant diagnostic and therapeutic challenges [2,3]. CNS vasculitis has been reported under a variety of descriptive terms including isolated CNS angiitis, idiopathic angiitis of the CNS, and primary angiitis or vasculitis of the CNS. In a range of inflammatory vascular process, vasculitis may affect the CNS vessels. Not having sensitive and specific laboratory tests and rarity of disorders in one hand, and limitation in access to pathological evaluation of disease, on the other hand considered it as a very challenging clinical problem. Lack of specific signs and symptoms make more difficulty in diagnosis of this disorder [2].

CNS vasculitis can cause brain damage with reversible and or irreversible neurologic involvement, including acute ischemic attack, progressive cognitive decline and seizures often with intractable pattern. Headaches and concentration problems can be leading, to mood changes, significant school problems, personality and behavioral abnormalities [3-5]. Acute and or chronic inflammatory course of vasculitis may causes severe neurological impairment or also death. When the vessels become inflamed as a consequence of less blood flow brain tissue may be damaged. Studies have shown that early diagnosis and aggressive treatment result in improved neurological outcome and reduced mortality [6-8]. If untreated, this condition can lead to permanent damage of the brain tissue [9,10].

In the past, childhood primary angiitis of the CNS (cPACNS) was thought to be a rare disease. [11,12]. More commonly, CNS vessels inflammation had been described in association with an identifiable systemic condition (secondary CNS vasculitis) such as an infectious process [13,14], systemic vasculitis [15,16], a collagen-vascular disease [17,18] a systemic inflammatory disease [15] or specific malignancy [19,20].

Cravioto and Feigin [13] reported a first case of primary CNS vasculitis with “noninfectious granulomatous angiitis with predilection for the nervous system. Calabrese et al. [21] the pioneer of CNS vasculitis, coined the term “primary angiitis of the CNS (PACNS)” in 1987. Calabrese proposed and validated diagnostic criteria for PACNS in adults: an acquired neurological deficit, plus angiographic or histopathology features of angiitis within the CNS, in the absence of a systemic vasculitis or any other condition to which the angiographic or pathologic features could be secondary [22,23]. These criteria have since been adopted for childhood primary angiitis of CNS (cPACNS) by pediatric neurologists and rheumatologists [24-27]. In 2001, Lanthier reported two cases of biopsy-proven cPACNS [2]. The same year, Gallagher et al. [1] reported five children with angiography positive primary CNS vasculitis concomitantly. Since then the recognition of childhood CNS vasculitis in the absence of a systemic vasculitis or disease appears to be increased [27]. This case series work as a single-center study represents 22 cPACNS patients and describe their clinical and imaging characteristics with arteriography evidence of cPACNS.

2. Methods

From 1994 to 2021 at pediatric rheumatology and FMF clinic, patients <18 years of age were included to this study as having cPACNS if they had: 1) A clinical diagnosis of primary CNS vasculitis on the basis of neurological findings, and 2) Magnetic resonance angiography (MRA) findings demonstrating arterial stenosis, aneurism, lack of vascularity not attributable to other causes. (Calabrese criteria: an acquired neurological deficit, plus angiographic or histopathology features of angiitis within the CNS, in the absence of a systemic vasculitis or any other condition to which the angiographic or pathologic features could be secondary [22,23].)

The study excluded patients and children with systemic vaculities, children with collagen vascular disease, and other defined conditions known to cause vascular involvment.

Clinical symptoms were categorized as headaches, seizures, focal neurologic deficits (hemiparesis, hemifacial weakness, and hemisensory and fine motor deficits), diffuse neurologic deficits (altered concentration, cognition, mood, or personality), and constitutional symptoms (fever, fatigue, and weight loss).Administration of drug therapy was considered on a case by- case basis and condition.

The study is complaint with the Helsinki Declaration and was approved by the local Ethics Committee under number (IR.ARUMS.REC.1393.0476). Informed consent was obtained from all parents individual participants included in the study. Simple statistical method has been done by SPSS Ver.18

3. Results

22 patients were enrolled this study, 12 patients (54%) were female, the youngest was 3 years old and the oldest one was 17 years old (mean10 yr.). The mean delayed time to diagnosis was 4 years. The most common neurologic symptoms in our series were headaches (88%), seizure and mental disorder in (45%). Systemic symptoms such as fever, decreased energy level and weakness were common findings 54%, 45%, 31% respectively. The main complaint of patients was headache (68%) then fever (54%). Laboratory results in our series showed mild anemia (63%) and leukocytosis (45%). ESR and CRP were in high results in (40%). ANA was positive in (31%) but not in significant high titers. Small vessels involvements were in 14 (63%) patients, four patients had large vessels involvement and in the rest (4 patients) showed both vessels involvement. 14 patients (63 %) showed abnormality in both MCA and ACA, whereas PCA showed this abnormity in 36% (8) patients. Most of patients 86 % (19) had normal EEG findings. Table1 shows some characteristic features of all patients.

Table 1: Patients’ symptoms and signs.

4. Discussion and Conclusions

cPACNS is a primary immune mediated inflammatory disorder of CNS vessels. It is hypothesized that reactivated Varicella Zoster virus (VZV) and other neurotropic viruses can induce a post infectious type of CNS vasculitis and it has been proposed that viral infections such as Parvovirus B19 has been reported to trigger CNS vasculitis among immune-suppressed pediatric patients [28] however, these patients usually have a long prodromal period and less constitutional symptoms with few patients presenting so far [29].

Signs and symptoms of systemic vasculitis such as peripheral neuropathy, fever, weight loss or rash are usually absent [30]. In our study Systemic symptoms such as fever, decreased energy level and weakness were common findings 54%, 45%, 31% respectively. The main complaints of patients in this study were headache (68%) then fever (54%) and seizure with mental disorder in (45%). CNS vasculitis is usually suspected when recurrent vascular events occur in young patients with no identifiable risk factors, or in the setting of chronic and progressive unexplained CNS disorder [30]. In one study focal neurologic deficits were the most frequent clinical symptom, including acute hemiparesis (80%), hemi-sensory deficit (79%), and fine motor deficits (73%). Headaches were present in 56% of patients and seizures in 15%. Diffuse neurologic deficits included mood/personality changes in 26%, cognitive dysfunction in 37%, and concentration difficulties in 29% of patients. Concentration difficulties and cognitive dysfunction resulted in decline in school performance and participation [31].

A study conducted by Benseler et al. [7,27] on children with initial diagnosis of cerebral vasculitis (the proof was based on the findings of angiography and MRA) 62 children (38 male, 27 female, mean age 2/7 years) with a diagnosis of primary CNS vasculitis were divided into two groups with progressive disease (20 patients) and non-progressive disease (42 patients). Neurologic symptoms such as cognitive impairment, attention and mood disorders in patients with progressive disease were significantly higher than other groups (p<001/0).

The spectrum of cPACNS includes three distinct disease entities: progressive angiography-positive cPACNS (P-cPACNS); non-progressive angiography-positive cPACNS (NP-cPACNS); and angiography-negative, small-vessel cPACNS (SV-cPACNS) [27,31].

Proximal, large-vessel inflammation with subsequent focal stenosis is the hallmark of non-progressive angiography-positive NP-cPACNS. NP-cPACNS patients often present with unilateral MRI lesions predominantly focal deficits, and proximal vessel stenosis on angiography [31]. These patients have a monophasic inflammatory large-vessel disease, which does not progress beyond 3 months. The majority of NP-cPACNS patients present with strokes.

In contrast, Patients with progressive angiography-positive, P-cPACNS frequently present with multifocal MRI lesions and evidence of both proximal and distal vessels stenosis on angiography and both focal and diffuse neurological findings. Untreated patients will progress beyond 3 months [27].

P-cPACNS patients have both large and small-vessel inflammation and will therefore present with overlapping clinical features including cognitive and behavior changes. Distal vessels inflammation is commonly seen in progressive angiography-positive P-cPACNS vasculitis.

Children with angiography-negative, small-vessel SV-cPACNS present with distal vessels stenosis and multifocal MRI lesions with significant diffuse neurological deficits including cognitive decline, behavior changes, school difficulties, and mood/personality changes. Angiography remains normal and brain biopsies confirm the diagnosis of SV-cPACNS [32-35].

Laboratory results although in different reports did not show specific findings, systemic inflammatory markers are frequently normal in children with cPACNS. Some children may have positive antinuclear antibodies (ANA) [11,29].

However, as the inflammation progresses, some children may develop mildly elevated systemic inflammatory markers. [27,29] A normal erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), white blood cell count (WBC), C3 complement, or immunoglobulin levels by no means exclude an active vasculitis process in the CNS. In our series anemia (63%) and leukocytosis (45%) were common abnormalities. ESR and CRP were in high amounts in (40%) patients .ANA was positive in (31%) patients although not in significant and high titers.

Pathological and imaging studies (MRI, MRA, CT-SCAN and CA) are valuable tools for the diagnosis of cerebral vasculitis [36-40].

In this study CT-SCAN showed nonspecific abnormalities in three patients only, however in MRA study small vessels involvements were in 14 (63%) patients, which could be in favor of P-cPACNS. Four patients had large vessels involvement and in the rest (4 patients) both vessels were involved.14 patients (63 %) showed abnormality in both middle cerebral artery (MCA) and anterior cerebral artery (ACA), whereas posterior cerebral artery (PCA) showed this abnormity in 36% (8) patients. In six patients MRI showed some pathologic results and their simultaneous MRA had particular findings. Comparisons of the MRI and MRA findings of these patients have been shown in Table 2.

Table 2: Comparison of MRI and MRA findings.

There is not clear findings about EEG in this disorder, most patients 86 %( 19) in our group had normal EEG results.

In children, the choice of treatment depends on the cPACNS classification [41]. Intravenous (IV) monthly cyclophosphamide plus high-dose corticosteroids are the current method in patients with P-cPACNS and SV-cPACNS [25,29]. Induction therapy consists of seven IV cyclophosphamide pulses (500–1000 mg/m²/month) plus corticosteroids (2 mg/kg/day). Maintenance course follow with oral drugs such as azathioprine or mycophenolate mofetil plus a tapering low dose of corticosteroids for 2 years [41].

Approach of therapy was on a case by- case basis, diseases severity, neurologic handicap, drug tolerance and availability were additional parameter that we considered in therapy. Prednisolone (90%) Cyclophosmide (50%), MMF (50%), Azathioprne (45%), Methotrexate (9%) have been used. In spite of full course therapy, five patients (22%) had sever and permanent neurological sequel such as seizure, mental regress and personality disorders. At recent decade in all refractory cases our first choice of biologic therapy was infliximab (this protocole is under-investigate), most of them in view of subsiding clinical symptoms showed favorable response to this biologic treatment.

There are some limitations in this study such as lack of biopsy proven and tissue pathology that are not available in our centers, on the other hand long term period of study (25 years) made we could not follow accurately our patients because of changing of their follow up clinic by adult one.

Acknowledgements

None

Authors’ Contributions

FS: carried out the management and diagnosis of patients. OA and AH Participated in the design of the study and performed the statistical analysis and helped to draft the manuscript. All authors read and approved the final manuscript.

Funding

There is no funding in this study. Availability of data and materials please contact first author (Salehzadeh F.) for data request.

Ethics approval and consent to participate

This article does not contain any studies with human participants or animals performed by any of the authors. The study is complaint with the Helsinki Declaration and was approved by the local Ethics Committee under number (IR.ARUMS.REC.1393.0476). Informed consent was obtained from all parents individual participants included in the study.

Consent for publication:

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Gallagher KT, Shaham BR, Reiff AN, et al. Primary angiitis of the central nervous system in children: 5 cases. The Journal of rheumatology 28 (2001): 616-623.
2. Lanthier S, Lortie A, Michaud J, et al. Isolated angiitis of the CNS in children. Neurology 56 (2001): 837-842.
3. Benseler S, Schneider R. Central nervous system vasculitis in children. Current opinion in Rheumatology 16 (2004): 43-50.
4. Kraemer M, Berlit P. Primary central nervous system vasculitis: clinical experiences with 21 new European cases. Rheumatology International 31 (2011): 463-472.
5. Twilt M, Benseler SM. Central nervous system vasculitis in adults and children. Handbook of Clinical Neurology 133 (2016): 283-300.
6. Eleftheriou D, Cox T, Saunders D, et al. Investigation of childhood central nervous system vasculitis: magnetic resonance angiography versus catheter cerebral angiography. Developmental Medicine and Child Neurology 52 (2010): 863-867.
7. Benseler SM, deveber G, Hawkins C, et al. Angiography-negative primary central nervous system vasculitis in children: a newly recognized inflammatory central nervous system disease. Arthritis and Rheumatism 52 (2005): 2159-2167.
8. Friedman NR. Small vessel childhood primary angiitis of the CNS: first steps toward a standardised treatment regimen. The Lancet Neurology 9 (2010): 1042-1044.
9. Hutchinson C, Elbers J, Halliday W, et al. Treatment of small vessel primary CNS vasculitis in children: an open-label cohort study. The Lancet Neurology 9 (2010): 1078-1084.
10. Smitka M, Bruck N, Engellandt K, et al. Clinical perspective on primary angiitis of the central nervous system in childhood (cPACNS). Frontiers in Pediatrics 8 (2020): 281.
11. Cellucci T, Benseler SM. Diagnosing central nervous system vasculitis in children. Current opinion in Pediatrics 22 (2010): 731-738.
12. Calabrese LH, Duna GF, Lie JT. Vasculitis in the central nervous system. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology 40 (1997): 1189-1201.
13. Cravioto H, Feigin I. Noninfectious granulomatous angiitis with a predilection for the nervous system. Neurology 9 (1959): 599.
14. Ueno M, Oka A, Koeda T, et al. Unilateral occlusion of the middle cerebral artery after varicella-zoster virus infection. Brain and Development 24 (2002): 106-108.
15. Lloyd-Still JD, Tomasi L. Neurovascular and thromboembolic complications of inflammatory bowel disease in childhood. Journal of Pediatric Gastroenterology and Nutrition 9 (1989): 461-466.
16. Belostotsky VM, Shah V, Dillon MJ. Clinical features in 17 paediatric patients with Wegener granulomatosis. Pediatric Nephrology 17 (2002): 754-761.
17. Krespi Y, Akman-Demir G, Poyraz M, et al. Cerebral vasculitis and ischaemic stroke in Behçet’s disease: report of one case and review of the literature. European Journal of Neurology 8 (2001): 719-722.
18. Steens SC, Bosma GT, ten Cate R, et al. A neuroimaging follow up study of a patient with juvenile central nervous system systemic lupus erythematosus. Annals of the rheumatic diseases 62 (2003): 583-586.
19. Song DK, Boulis NM, McKeever PE, et al. Angiotropic large cell lymphoma with imaging characteristics of CNS vasculitis. American Journal of Neuroradiology 23 (2002): 239-242.
20. Sheehy N, Sheehan K, Brett F, et al. Hodgkins disease presenting with granulomatous angiitis of the central nervous system. Journal of Neurology 250 (2003): 112.
21. Calabrese LH, Furlan AJ, Gragg LA, et al. Primary angiitis of the central nervous system: diagnostic criteria and clinical approach. Cleveland Clinic Journal of Medicine 59 (1992): 293-306.
22. Brisman JL, Hinduja A, McKinney JS, et al. Successful emergent angioplasty of neurosarcoid vasculitis presenting with strokes. Surgical neurology 66 (2006): 402-404.
23. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Annals of the Rheumatic Diseases 68 (2009): 310-317.
24. Iannetti L, Zito R, Bruschi S, et al. Recent understanding on diagnosis and management of central nervous system vasculitis in children. Clinical and Developmental Immunology 1 (2012).
25. Calabrese LH, Mallek JA. Primary angiitis of the central nervous system. Report of 8 new cases, review of the literature, and proposal for diagnostic criteria. Medicine 67 (1988): 20-39.
26. Keenan P, Brunner J, Quan AS, et al. Diagnosis and Treatment of Small Vessel Childhood Primary Angiitis of the Central Nervous System (sv-cPACNS): An International Survey. Frontiers in pediatrics 9 (2021).
27. Benseler SM, Silverman E, Aviv RI, et al. Primary central nervous system vasculitis in children. Arthritis and Rheumatism 54 (2006): 1291-1297.
28. Malik MA, Zia-ur-Rehman M, Nadeem MM, et al. Childhood primary angiitis of the central nervous system. J Coll Physicians Surg Pak 22 (2012): 570-574.
29. Park MS, Marlin AE, Gaskill SJ. Angiography-negative primary angiitis of the central nervous system in childhood: Case report. Journal of Neurosurgery: Pediatrics 13 (2014): 62-67.
30. Rice CM, Scolding NJ. The diagnosis of primary central nervous system vasculitis. Practical Neurology 20 (2020): 109-114.
31. Aviv RI, Benseler SM, Silverman ED, et al. MR imaging and angiography of primary CNS vasculitis of childhood. American Journal of Neuroradiology 27 (2006): 192-199.
32. Benseler SM. Central nervous system vasculitis in children. Current Rheumatology Reports 8 (2006): 442-449.
33. Park MS, Marlin AE, Gaskill SJ. Angiography-negative primary angiitis of the central nervous system in childhood: Case report. Journal of Neurosurgery: Pediatrics 13 (2014): 62-67.
34. Zax RH, Hodge SJ, Callen JP. Cutaneous leukocytoclastic vasculitis: serial histopathologic evaluation demonstrates the dynamic nature of the infiltrate. Archives of Dermatology 126 (1990): 69-72.
35. Hunder GG, Lie JT, Goronzy JJ, et al. Pathogenesis of giant cell arteritis. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 36 (1993): 757-761.
36. Pipitone N, Salvarani C. Role of imaging in vasculitis and connective tissue diseases. Best Practice and Research Clinical Rheumatology 22 (2008): 1075-1091.
37. Aviv RI, Benseler SM, DeVeber G, et al. Angiography of primary central nervous system angiitis of childhood: conventional angiography versus magnetic resonance angiography at presentation. American Journal of Neuroradiology 28 (2007): 9-15.
38. Cellucci T, Benseler SM. Central nervous system vasculitis in children. Current Opinion in Rheumatology 22 (2010): 590-597.
39. Alrawi A, Trobe JD, Blaivas M, et al. Brain biopsy in primary angiitis of the central nervous system. Neurology 53 (1999): 858-860.
40. Hajj-Ali RA, Furlan A, Abou-Chebel A, et al. Benign angiopathy of the central nervous system: cohort of 16 patients with clinical course and long-term follow up. Arthritis Care and Research: Official Journal of the American College of Rheumatology 47 (2002): 662-669.
41. Beelen J, Benseler SM, Dropol A, et al. Strategies for treatment of childhood primary angiitis of the central nervous system. Neurology-Neuroimmunology Neuroinflammation 6 (2019).